JP2008529494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008529494A5 JP2008529494A5 JP2007554221A JP2007554221A JP2008529494A5 JP 2008529494 A5 JP2008529494 A5 JP 2008529494A5 JP 2007554221 A JP2007554221 A JP 2007554221A JP 2007554221 A JP2007554221 A JP 2007554221A JP 2008529494 A5 JP2008529494 A5 JP 2008529494A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- cell carcinoma
- kid24
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 43
- 210000004027 cell Anatomy 0.000 claims 41
- 201000011510 cancer Diseases 0.000 claims 23
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 15
- 206010038389 Renal cancer Diseases 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 15
- 201000010982 kidney cancer Diseases 0.000 claims 15
- 230000001394 metastastic effect Effects 0.000 claims 15
- 206010061289 metastatic neoplasm Diseases 0.000 claims 15
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims 10
- 208000005243 Chondrosarcoma Diseases 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 206010039491 Sarcoma Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 9
- 201000010881 cervical cancer Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000009030 Carcinoma Diseases 0.000 claims 6
- 206010024612 Lipoma Diseases 0.000 claims 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 208000008732 thymoma Diseases 0.000 claims 6
- 206010046766 uterine cancer Diseases 0.000 claims 6
- 208000030507 AIDS Diseases 0.000 claims 5
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 5
- 206010003571 Astrocytoma Diseases 0.000 claims 5
- 206010005003 Bladder cancer Diseases 0.000 claims 5
- 208000019838 Blood disease Diseases 0.000 claims 5
- 206010005949 Bone cancer Diseases 0.000 claims 5
- 208000018084 Bone neoplasm Diseases 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 201000009047 Chordoma Diseases 0.000 claims 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 5
- 206010014967 Ependymoma Diseases 0.000 claims 5
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 5
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims 5
- 208000021309 Germ cell tumor Diseases 0.000 claims 5
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 5
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 5
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 5
- 206010029260 Neuroblastoma Diseases 0.000 claims 5
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 5
- 208000000035 Osteochondroma Diseases 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 5
- 206010033963 Parathyroid tumour Diseases 0.000 claims 5
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 5
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 5
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims 5
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 5
- 206010057644 Testis cancer Diseases 0.000 claims 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 5
- 208000008383 Wilms tumor Diseases 0.000 claims 5
- 208000009956 adenocarcinoma Diseases 0.000 claims 5
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 5
- 208000012080 benign lipomatous neoplasm Diseases 0.000 claims 5
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 210000004556 brain Anatomy 0.000 claims 5
- 210000001715 carotid artery Anatomy 0.000 claims 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 5
- 208000029742 colonic neoplasm Diseases 0.000 claims 5
- 210000003298 dental enamel Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000003352 fibrogenic effect Effects 0.000 claims 5
- 210000000232 gallbladder Anatomy 0.000 claims 5
- 201000010175 gallbladder cancer Diseases 0.000 claims 5
- 206010017758 gastric cancer Diseases 0.000 claims 5
- 201000010536 head and neck cancer Diseases 0.000 claims 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims 5
- 208000014951 hematologic disease Diseases 0.000 claims 5
- 208000018706 hematopoietic system disease Diseases 0.000 claims 5
- 208000006359 hepatoblastoma Diseases 0.000 claims 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 5
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 5
- 208000003849 large cell carcinoma Diseases 0.000 claims 5
- 201000010260 leiomyoma Diseases 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 201000005252 lipomatous cancer Diseases 0.000 claims 5
- 206010024627 liposarcoma Diseases 0.000 claims 5
- 201000007270 liver cancer Diseases 0.000 claims 5
- 208000014018 liver neoplasm Diseases 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 208000030883 malignant astrocytoma Diseases 0.000 claims 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 206010027191 meningioma Diseases 0.000 claims 5
- 206010051747 multiple endocrine neoplasia Diseases 0.000 claims 5
- 201000008026 nephroblastoma Diseases 0.000 claims 5
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 5
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 5
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 5
- 201000008968 osteosarcoma Diseases 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 5
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 5
- 208000028591 pheochromocytoma Diseases 0.000 claims 5
- 208000010916 pituitary tumor Diseases 0.000 claims 5
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 5
- 201000000849 skin cancer Diseases 0.000 claims 5
- 201000011096 spinal cancer Diseases 0.000 claims 5
- 208000014618 spinal cord cancer Diseases 0.000 claims 5
- 201000011549 stomach cancer Diseases 0.000 claims 5
- 206010042863 synovial sarcoma Diseases 0.000 claims 5
- 201000003120 testicular cancer Diseases 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 201000002510 thyroid cancer Diseases 0.000 claims 5
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 5
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 5
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims 5
- 206010004593 Bile duct cancer Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 208000010932 epithelial neoplasm Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 201000010103 fibrous dysplasia Diseases 0.000 claims 4
- 201000002529 islet cell tumor Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000011164 ossification Effects 0.000 claims 4
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 4
- 208000025443 tumor of adipose tissue Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000000649 small cell carcinoma Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000013558 Developmental Bone disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 1
- 201000000284 histiocytoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64978705P | 2005-02-02 | 2005-02-02 | |
| US60/649,787 | 2005-02-02 | ||
| PCT/US2006/003748 WO2006084075A2 (en) | 2005-02-02 | 2006-02-02 | Adam-9 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008529494A JP2008529494A (ja) | 2008-08-07 |
| JP2008529494A5 true JP2008529494A5 (enExample) | 2009-04-02 |
| JP5328155B2 JP5328155B2 (ja) | 2013-10-30 |
Family
ID=36777934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554221A Expired - Fee Related JP5328155B2 (ja) | 2005-02-02 | 2006-02-02 | Ａｄａｍ−９モジュレータ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7674619B2 (enExample) |
| EP (1) | EP1841794B1 (enExample) |
| JP (1) | JP5328155B2 (enExample) |
| KR (1) | KR101317358B1 (enExample) |
| CN (1) | CN101142236B (enExample) |
| AU (1) | AU2006210589B2 (enExample) |
| CA (1) | CA2596273C (enExample) |
| IL (1) | IL184657A (enExample) |
| MX (1) | MX2007009222A (enExample) |
| NZ (1) | NZ556561A (enExample) |
| WO (1) | WO2006084075A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2596273C (en) | 2005-02-02 | 2017-11-14 | Raven Biotechnologies, Inc. | Adam-9 modulators |
| AU2007336243B2 (en) | 2006-12-19 | 2012-07-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| EP2109668A4 (en) | 2007-01-22 | 2011-10-05 | Macrogenics West Inc | HUMAN CANCER STEM CELLS |
| JP5785490B2 (ja) | 2008-04-02 | 2015-09-30 | マクロジェニクス，インコーポレーテッド | Ｂｃｒ複合体特異的抗体およびその使用方法 |
| US20090285840A1 (en) * | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
| EP2331145B1 (en) * | 2008-09-22 | 2014-12-17 | F. Hoffmann-La Roche AG | Method for determining the anti-tumor efficacy of monoclonal antibodies |
| ES2733067T3 (es) | 2008-12-19 | 2019-11-27 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| JP2012517821A (ja) * | 2009-02-19 | 2012-08-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物 |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| MX339622B (es) | 2010-08-02 | 2016-06-02 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| EA201391753A1 (ru) | 2011-05-21 | 2014-08-29 | Макродженикс, Инк. | Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| AU2016298227B9 (en) | 2015-07-30 | 2019-10-31 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| SI3558391T1 (sl) * | 2016-12-23 | 2022-06-30 | Immunogen, Inc. | Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe |
| AU2017382234B2 (en) * | 2016-12-23 | 2025-01-30 | Macrogenics, Inc. | ADAM9-binding molecules, and methods of use thereof |
| JP7132232B2 (ja) | 2017-02-24 | 2022-09-06 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
| AU2018345601B2 (en) | 2017-10-02 | 2025-05-15 | Verra Therapeutics LLC | Methods and compositions for inhibiting ADAM10 biological activities |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| AU2019215009B2 (en) * | 2018-01-31 | 2025-08-21 | Verra Therapeutics LLC | Methods and compositions for inhibiting ADAM 9 biological activities |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| MX2020013466A (es) | 2018-06-26 | 2021-04-19 | Immunogen Inc | Inmunoconjugados dirigidos a adam9 y métodos para usarlos. |
| US20240165256A1 (en) * | 2021-03-08 | 2024-05-23 | Immunogen, Inc. | Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (enExample) | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| USRE30548E (en) | 1979-08-31 | 1981-03-17 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| EP0933423B1 (en) * | 1996-02-23 | 2007-08-22 | Mochida Pharmaceutical Co., Ltd. | Meltrins |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| EP1259595B1 (en) | 2000-02-25 | 2007-04-04 | Immunex Corporation | Integrin antagonists |
| EP1142910A1 (en) | 2000-04-07 | 2001-10-10 | Jürgen Prof. Dr. Frey | Inhibitors for the formation of soluble human CD23 |
| US20030091568A1 (en) * | 2000-04-07 | 2003-05-15 | Jurgen Frey | Inhibitors for the formation of soluble human CD23 |
| AU2002315306B2 (en) * | 2001-05-08 | 2007-05-17 | Merck Patent Gmbh | Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US20040091473A1 (en) | 2001-07-27 | 2004-05-13 | Dubose Robert F. | Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| US20040048319A1 (en) * | 2002-05-03 | 2004-03-11 | Mather Jennie P. | ALCAM and ALCAM modulators |
| ATE488530T1 (de) * | 2002-06-19 | 2010-12-15 | Raven Biotechnologies Inc | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel |
| AU2003270625A1 (en) * | 2002-09-11 | 2004-04-30 | Justus-Liebig-Universität Giessen | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
| EP1572131B1 (en) * | 2002-10-08 | 2016-07-06 | Immunomedics, Inc. | Antibody therapy |
| US7405061B2 (en) * | 2002-11-13 | 2008-07-29 | Raven Biotechnologies, Inc. | Antigen PIPA and antibodies that bind thereto |
| EP1664283A4 (en) | 2003-09-18 | 2007-12-26 | Raven Biotechnologies Inc | CELL CULTURE MEDIA |
| CA2596273C (en) | 2005-02-02 | 2017-11-14 | Raven Biotechnologies, Inc. | Adam-9 modulators |
-
2006
- 2006-02-02 CA CA2596273A patent/CA2596273C/en not_active Expired - Fee Related
- 2006-02-02 EP EP06720179.8A patent/EP1841794B1/en not_active Expired - Lifetime
- 2006-02-02 KR KR1020077018810A patent/KR101317358B1/ko not_active Expired - Fee Related
- 2006-02-02 CN CN2006800087418A patent/CN101142236B/zh not_active Expired - Fee Related
- 2006-02-02 WO PCT/US2006/003748 patent/WO2006084075A2/en not_active Ceased
- 2006-02-02 MX MX2007009222A patent/MX2007009222A/es active IP Right Grant
- 2006-02-02 JP JP2007554221A patent/JP5328155B2/ja not_active Expired - Fee Related
- 2006-02-02 NZ NZ556561A patent/NZ556561A/en not_active IP Right Cessation
- 2006-02-02 AU AU2006210589A patent/AU2006210589B2/en not_active Ceased
- 2006-02-02 US US11/346,779 patent/US7674619B2/en not_active Expired - Fee Related
-
2007
- 2007-07-17 IL IL184657A patent/IL184657A/en not_active IP Right Cessation
-
2010
- 2010-01-14 US US12/687,512 patent/US8361475B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532488A5 (enExample) | ||
| JP2010508847A5 (enExample) | ||
| JP2005532050A5 (enExample) | ||
| US9982063B2 (en) | Pharmaceutical compositions with resistance to soluble CEA | |
| CN102421802B (zh) | 人源化的axl抗体 | |
| JP2010110329A5 (enExample) | ||
| JP6113933B1 (ja) | 繊維芽細胞増殖因子受容体３（ｆｇｆｒ３）に対する化合物および治療的使用 | |
| WO2019024911A1 (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| JP2009297037A5 (enExample) | ||
| JP2013529059A5 (enExample) | ||
| JP2010510809A5 (enExample) | ||
| JP2020522494A5 (enExample) | ||
| JP2005538701A5 (enExample) | ||
| JP2005505256A5 (enExample) | ||
| JP2008526256A5 (enExample) | ||
| TWI781647B (zh) | 抗人神經降壓素受體抗體及其用途 | |
| JP2008508858A5 (enExample) | ||
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 | |
| CN103025760A (zh) | 人源化egfr抗体 | |
| JP2008538173A5 (enExample) | ||
| CN115998900A (zh) | 抗trop-2抗体药物偶联物及其医药用途 | |
| JP2025508380A5 (enExample) | ||
| JP2021531263A (ja) | 抗ヒトｐｄ−ｌ１抗体とその使用 | |
| US20250288687A1 (en) | Combination of antibody-drug conjugates and dnmt inhibitors | |
| AU2024368294A1 (en) | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein |